Vancouver, British Columbia--(Newsfile Corp. - April 4, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) (" Entheon " or the " Company ") announces the appointment of Harrison Newlands to the Company's Board of Directors, effective April 3, 2025. Harrison Newlands has a diverse understanding of start-ups and capital markets, having invested, advised, and helped co-found dozens of mid-cap companies... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) (" Entheon " or the " Company ") announces that the Company has granted options to purchase up to an aggregate 40,000 common shares in the Company (the "Options") to certain directors of the Company. The Options are exercisable at $0.145 per share for a period of two years from the date of grant.... Read More

Vancouver, British Columbia--(Newsfile Corp. - March 14, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) (" Entheon " or the " Company ") announces that, further to its news release dated January 24, 2025, 1000141080 Ontario Ltd. (" Mentis AI ") has terminated the letter of intent (" LOI ") dated January 23, 2025 which set out the terms whereby Entheon would acquire all of the issued and outstanding... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 24, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) (" Entheon " or the " Company ") is pleased to announce that it has entered into a binding letter of intent (" LOI ") dated January 23, 2025 with 1000141080 Ontario Ltd. (" Mentis AI "), pursuant to which Entheon will acquire all of the issued and outstanding common shares in the capital of Mentis... Read More